Jessica Hope Roark

Array ( [id] => 10361113 [patent_doc_number] => 20150246118 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-03 [patent_title] => 'LYVE-1 ANTAGONISTS FOR PREVENTING OR TREATING A PATHOLOGICAL CONDITION ASSOCIATED WITH LYMPHANGIOGENESIS' [patent_app_type] => utility [patent_app_number] => 14/438465 [patent_app_country] => US [patent_app_date] => 2013-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 24943 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14438465 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9449384 [patent_doc_number] => 20140120554 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-01 [patent_title] => 'ANTI CEACAM1 ANTIBODIES AND METHODS OF USING SAME' [patent_app_type] => utility [patent_app_number] => 14/061277 [patent_app_country] => US [patent_app_date] => 2013-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 10064 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14061277 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9512093 [patent_doc_number] => 20140148584 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-29 [patent_title] => 'EPHB3-SPECIFIC ANTIBODY AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/055376 [patent_app_country] => US [patent_app_date] => 2013-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 43594 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14055376 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13154055 [patent_doc_number] => 10093740 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-09 [patent_title] => Bispecific HER2 ligands for cancer therapy [patent_app_type] => utility [patent_app_number] => 14/430224 [patent_app_country] => US [patent_app_date] => 2013-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 33 [patent_no_of_words] => 22561 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14430224 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9293991 [patent_doc_number] => 20140037625 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-06 [patent_title] => 'BIOMARKERS AND METHODS OF TREATMENT' [patent_app_type] => utility [patent_app_number] => 14/046867 [patent_app_country] => US [patent_app_date] => 2013-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 41487 [patent_no_of_claims] => 78 [patent_no_of_ind_claims] => 19 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14046867 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10405306 [patent_doc_number] => 20150290316 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-15 [patent_title] => 'COMBINATION OF ANTI-KIR ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREAT CANCER' [patent_app_type] => utility [patent_app_number] => 14/432376 [patent_app_country] => US [patent_app_date] => 2013-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 19926 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14432376 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11343508 [patent_doc_number] => 09527903 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-12-27 [patent_title] => 'Engineered antibody constant domain molecules' [patent_app_type] => utility [patent_app_number] => 14/043366 [patent_app_country] => US [patent_app_date] => 2013-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 34 [patent_no_of_words] => 29995 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14043366 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9944429 [patent_doc_number] => 08993730 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-03-31 [patent_title] => 'BCR-complex-specific antibodies and methods of using same' [patent_app_type] => utility [patent_app_number] => 14/034433 [patent_app_country] => US [patent_app_date] => 2013-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 31373 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14034433 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10389829 [patent_doc_number] => 20150274836 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-01 [patent_title] => 'MESOTHELIN ANTIBODIES AND METHODS FOR ELICITING POTENT ANTITUMOR ACTIVITY' [patent_app_type] => utility [patent_app_number] => 14/428771 [patent_app_country] => US [patent_app_date] => 2013-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 21909 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14428771 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19274457 [patent_doc_number] => 12024568 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-02 [patent_title] => Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies [patent_app_type] => utility [patent_app_number] => 14/426347 [patent_app_country] => US [patent_app_date] => 2013-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 18129 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 157 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14426347 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9204933 [patent_doc_number] => 20140004110 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-01-02 [patent_title] => 'ANTI CD37 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 13/974230 [patent_app_country] => US [patent_app_date] => 2013-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 20486 [patent_no_of_claims] => 53 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13974230 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10038183 [patent_doc_number] => 09078879 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-07-14 [patent_title] => 'Anti CD37 antibodies' [patent_app_type] => utility [patent_app_number] => 13/974226 [patent_app_country] => US [patent_app_date] => 2013-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 20493 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13974226 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10367113 [patent_doc_number] => 20150252118 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-10 [patent_title] => 'MESOTHELIN DOMAIN-SPECIFIC MONOCLONAL ANTIBODIES AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/421599 [patent_app_country] => US [patent_app_date] => 2013-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 22202 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14421599 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9318384 [patent_doc_number] => 20140050722 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-20 [patent_title] => 'CHIMERIC ANTI-RICIN ANTIBODY' [patent_app_type] => utility [patent_app_number] => 13/967977 [patent_app_country] => US [patent_app_date] => 2013-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 15134 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13967977 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9490583 [patent_doc_number] => 20140140989 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-22 [patent_title] => 'Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof' [patent_app_type] => utility [patent_app_number] => 13/960136 [patent_app_country] => US [patent_app_date] => 2013-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 36258 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13960136 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9134897 [patent_doc_number] => 20130295612 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-07 [patent_title] => 'ANTI-GLYPICAN-3 ANTIBODY HAVING IMPROVED KINETICS IN PLASMA' [patent_app_type] => utility [patent_app_number] => 13/924957 [patent_app_country] => US [patent_app_date] => 2013-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 32250 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13924957 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9338361 [patent_doc_number] => 20140065143 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-03-06 [patent_title] => 'Inhibition of AXL Signaling in Anti-Metastatic Therapy' [patent_app_type] => utility [patent_app_number] => 13/950111 [patent_app_country] => US [patent_app_date] => 2013-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 21595 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13950111 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10149058 [patent_doc_number] => 09181333 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-11-10 [patent_title] => 'RSPO3 binding agents and uses thereof' [patent_app_type] => utility [patent_app_number] => 13/940834 [patent_app_country] => US [patent_app_date] => 2013-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 22 [patent_no_of_words] => 63661 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13940834 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10522715 [patent_doc_number] => 09249214 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-02-02 [patent_title] => 'Monoclonal antibodies for Ebola and Marburg viruses' [patent_app_type] => utility [patent_app_number] => 13/940712 [patent_app_country] => US [patent_app_date] => 2013-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 4065 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13940712 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10110050 [patent_doc_number] => 09145454 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-09-29 [patent_title] => 'Monoclonal antibodies for Ebola and Marburg viruses' [patent_app_type] => utility [patent_app_number] => 13/940688 [patent_app_country] => US [patent_app_date] => 2013-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 4222 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13940688 [rel_patent_id] =>[rel_patent_doc_number] =>)